Belarus vs Kyrgyzstan: Tuberculosis patients who tested positive for HIV
Belarus
128 patients
in 2021
Kyrgyzstan
126 patients
in 2021
Belarus rank
78th
Kyrgyzstan rank
79th
Tuberculosis patients who tested positive for HIV over time
- Belarus
- Kyrgyzstan
How they compare
Belarus currently reports 128 patients against 126 patients in Kyrgyzstan, a difference of 2 patients.
The two have swapped places 4 times across 14 shared years of data; in 2008 it was Belarus ahead.
Belarus ranks 78th and Kyrgyzstan ranks 79th of 201 countries.
Belarus has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Belarus | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 173 patients | 102.5 patients | 70.5 patients | Belarus |
| 2010s | 217.9 patients | 186.1 patients | 31.8 patients | Belarus |
| 2020s | 131.5 patients | 128.5 patients | 3 patients | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients who tested positive for hiv, Belarus or Kyrgyzstan?
- Belarus, at 128 patients against 126 patients in Kyrgyzstan as of 2021.
- What is the difference in tuberculosis patients who tested positive for hiv between Belarus and Kyrgyzstan?
- 2 patients, with Belarus ahead.
- How many years of comparable data are there for Belarus and Kyrgyzstan?
- 14 years are reported by both, from 2008 to 2021.
- How do Belarus and Kyrgyzstan rank globally for tuberculosis patients who tested positive for hiv?
- Belarus ranks 78th and Kyrgyzstan ranks 79th of 201 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients who tested positive for HIV. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of tuberculosis (new and relapsed) patients that tested positive for HIV.